Zhongmou Therapeutics
Clinical trials sponsored by Zhongmou Therapeutics, explained in plain language.
-
Gene therapy injection aims to halt blinding eye disease
Disease control Not yet recruitingThis early-stage trial tests a gene therapy called AGX-08 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. The study will involve 24 people aged 50 and older, each receiving a single injection into one eye. The main goal is to …
Phase: EARLY_PHASE1 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy injection aims to save sight in rare eye disease
Disease control Not yet recruitingThis early-stage trial tests a single injection of ZM-02, a gene therapy, in 21 people aged 6 to 60 with advanced retinitis pigmentosa, a genetic condition that causes progressive vision loss. Participants are randomly assigned to receive either a low or high dose of ZM-02 or a s…
Phase: PHASE1, PHASE2 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC